| __timestamp | Amicus Therapeutics, Inc. | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 20717000 | 5078000000 |
| Thursday, January 1, 2015 | 47269000 | 4717000000 |
| Friday, January 1, 2016 | 71151000 | 5096000000 |
| Sunday, January 1, 2017 | 88671000 | 4986000000 |
| Monday, January 1, 2018 | 127200000 | 4214000000 |
| Tuesday, January 1, 2019 | 169861000 | 3806000000 |
| Wednesday, January 1, 2020 | 156407000 | 3671000000 |
| Friday, January 1, 2021 | 192710000 | 3528000000 |
| Saturday, January 1, 2022 | 213041000 | 3445000000 |
| Sunday, January 1, 2023 | 275270000 | 3498000000 |
| Monday, January 1, 2024 | 3702000000 |
Data in motion
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Teva Pharmaceutical Industries Limited and Amicus Therapeutics, Inc. have showcased contrasting trends in their SG&A efficiency.
From 2014 to 2023, Teva's SG&A expenses have seen a significant decline, dropping from approximately $5 billion to $3.5 billion, reflecting a 30% reduction. This suggests a strategic shift towards cost efficiency. In contrast, Amicus Therapeutics has experienced a dramatic increase in SG&A expenses, rising from $21 million to $275 million, marking a staggering 1200% growth. This could indicate aggressive expansion or increased operational costs.
These trends highlight the diverse strategies employed by pharmaceutical companies in managing operational costs, offering valuable insights into their financial health and strategic priorities.
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Bio-Techne Corporation
Teva Pharmaceutical Industries Limited vs Viking Therapeutics, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Teva Pharmaceutical Industries Limited and Protagonist Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Teva Pharmaceutical Industries Limited and Soleno Therapeutics, Inc.
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Mesoblast Limited
Breaking Down SG&A Expenses: Teva Pharmaceutical Industries Limited vs Iovance Biotherapeutics, Inc.
Teva Pharmaceutical Industries Limited vs Celldex Therapeutics, Inc.: SG&A Expense Trends
Amicus Therapeutics, Inc. or Vericel Corporation: Who Manages SG&A Costs Better?
Amicus Therapeutics, Inc. and HUTCHMED (China) Limited: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Amicus Therapeutics, Inc. vs Protagonist Therapeutics, Inc. Trends and Insights
Breaking Down SG&A Expenses: Amicus Therapeutics, Inc. vs Mesoblast Limited
Selling, General, and Administrative Costs: Amicus Therapeutics, Inc. vs Travere Therapeutics, Inc.